At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
Atezolizumab-Bevacizumabdrug
Likely dose
Atezolizumab-Bevacizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
In Brief
A Phase 2 clinical trial evaluating Atezolizumab-Bevacizumab for Non Small Cell Lung Cancer. Completed, enrolled 41 participants across 25 sites.
Detailed Summary
This is a multi-center phase II clinical trial of atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastasic high-intermediate tumour mutation burden selected NSCLC patients. 102 patients will be enrolled in this trial to examine the efficacy of this combination measured by progression free survival according to response evaluation Criteria in solid tumours (RECIST) version 1.1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMay 2019
Primary CompletionOct 2024
TodayJul 2026
First PostedFeb 11, 2019
Enrollment StartMay 15, 2019
Primary CompletionOct 21, 2024
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 7.4 years ago
Interventions
Atezolizumab-Bevacizumabdrug
Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg